SEC Company Response from Q (QCLS) — Jan 17, 2014
Q/C TECHNOLOGIES, INC. (QCLS) (CIK 0001321834)
Date: Jan. 17, 2014 · CIK: 0001321834 · Accession: 0001144204-14-002729
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-190456
Letter
Division of Corporation Finance Re: Akers Bioscience, Inc. Registration Statement on Form S-1/A Filed on January 22, 2014 File No. 333-190456
Dear Mr. Riedler:
Akers Biosciences, Inc. (the “Company”) respectfully requests, pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), that the U.S. Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above captioned Registration Statement (the “Filing”) so that it may become effective at 5:15 p.m. Eastern Standard Time on January 22, 2014 or as soon thereafter as practicable. The Company would also appreciate telephone notice of such effectiveness to Joseph Lucosky at (732) 395-4402.
In connection with the Company’s request for acceleration of effectiveness of the Filing , the Company acknowledges the following:
(1) Should the Commission or the staff, acting pursuant to delegated authority, declare the Filing effective, it does not foreclose the Commission from taking any action with respect to the Filing;
(2) The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Filing; and
(3) The Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities law of the United States.
Very Truly Yours,
/s/ Thomas A. Nicolette
Show Raw Text
CORRESP
1
filename1.htm
AKERS
bioscienceS, inc.
201
GROVE ROAD
THOROFARE,
NJ 08086
January
17, 2014
Via
E-mail
Jeffrey P. Riedler
Assistant Director
U.S. Securities & Exchange
Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Akers Bioscience, Inc.
Registration Statement on Form S-1/A
Filed on January 22, 2014
File No. 333-190456
Dear Mr.
Riedler:
Akers Biosciences, Inc.
(the “Company”) respectfully requests, pursuant to Rule 461 under the Securities Act of 1933, as amended
(the “Act”), that the U.S. Securities and Exchange Commission (the “Commission”) accelerate the
effective date of the above captioned Registration Statement (the “Filing”) so that it may become effective at
5:15 p.m. Eastern Standard Time on January 22, 2014 or as soon thereafter as practicable. The Company would also appreciate
telephone notice of such effectiveness to Joseph Lucosky at (732) 395-4402.
In connection with the Company’s
request for acceleration of effectiveness of the Filing , the Company acknowledges the following:
(1) Should the Commission or the staff, acting pursuant to delegated authority,
declare the Filing effective, it does not foreclose the Commission from taking any action with respect to the Filing;
(2) The action of the Commission or the staff, acting pursuant to delegated authority,
in declaring the Filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the
disclosure in the Filing; and
(3) The Company may not assert staff comments and the declaration of effectiveness
as a defense in any proceeding initiated by the Commission or any person under the federal securities law of the United States.
Very Truly Yours,
/s/ Thomas A. Nicolette
Thomas A. Nicolette
Chief Executive Officer
Akers Biosciences, Inc.